These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27189067)

  • 1. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013.
    Norhammar A; Bodegård J; Nyström T; Thuresson M; Eriksson JW; Nathanson D
    Diabetologia; 2016 Aug; 59(8):1692-701. PubMed ID: 27189067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
    Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
    Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' follow-up.
    Jansson SP; Svärdsudd K; Andersson DK
    Diabet Med; 2014 Sep; 31(9):1055-63. PubMed ID: 24894815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
    Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ
    Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients.
    Eeg-Olofsson K; Cederholm J; Nilsson PM; Zethelius B; Nunez L; Gudbjörnsdóttir S; Eliasson B
    Diabetologia; 2009 Jan; 52(1):65-73. PubMed ID: 18985314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
    Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
    Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users.
    Nunes AP; Iglay K; Radican L; Engel SS; Yang J; Doherty MC; Dore DD
    Diabetes Obes Metab; 2017 Oct; 19(10):1425-1435. PubMed ID: 28497592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study.
    Jernberg T; Lindholm D; Hasvold LP; Svennblad B; Bodegård J; Sundell Andersson K; Thuresson M; Erlinge D; Janzon M
    BMJ Open; 2019 Apr; 9(4):e027199. PubMed ID: 30948612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
    Ritsinger V; Malmberg K; Mårtensson A; Rydén L; Wedel H; Norhammar A
    Lancet Diabetes Endocrinol; 2014 Aug; 2(8):627-33. PubMed ID: 24831989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E; DeFronzo RA
    Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.
    Rawshani A; Rawshani A; Franzén S; Eliasson B; Svensson AM; Miftaraj M; McGuire DK; Sattar N; Rosengren A; Gudbjörnsdottir S
    N Engl J Med; 2017 Apr; 376(15):1407-1418. PubMed ID: 28402770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K; Persson U
    J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
    Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
    Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and incidence of Type 2 diabetes and its complications 1996-2003--estimates from a Swedish population-based study.
    Ringborg A; Lindgren P; Martinell M; Yin DD; Schön S; Stålhammar J
    Diabet Med; 2008 Oct; 25(10):1178-86. PubMed ID: 19046196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.